Study of COVID-19 Infection, its Severity and Outcome in COVID-19 Vaccinated People at Tertiary Health Care Center, North West Rajasthan.
A Thathai, R Gahlot, NK Gahlot, MM Singh… - The Journal of the …, 2021 - europepmc.org
The Journal of the Association of Physicians of India, 2021•europepmc.org
Objective Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative
agent of corona virus-induced disease 19 (COVID-19) that was declared as a global
pandemic in March 2020 by the world health organization (WHO). Two vaccines were
granted for emergency use by the Central Drugs Standard Control Organization (CDSCO) in
India, Covishield®(AstraZeneca's vaccine manufactured by Serum Institute of India) and
Covaxin®(manufactured by Bharat Biotech Limited). Sputnik-V has been granted EUA in the …
agent of corona virus-induced disease 19 (COVID-19) that was declared as a global
pandemic in March 2020 by the world health organization (WHO). Two vaccines were
granted for emergency use by the Central Drugs Standard Control Organization (CDSCO) in
India, Covishield®(AstraZeneca's vaccine manufactured by Serum Institute of India) and
Covaxin®(manufactured by Bharat Biotech Limited). Sputnik-V has been granted EUA in the …
Objective
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of corona virus-induced disease 19 (COVID-19) that was declared as a global pandemic in March 2020 by the world health organization (WHO). Two vaccines were granted for emergency use by the Central Drugs Standard Control Organization (CDSCO) in India, Covishield®(AstraZeneca's vaccine manufactured by Serum Institute of India) and Covaxin®(manufactured by Bharat Biotech Limited). Sputnik-V has been granted EUA in the month of April 2021. The purpose of this study is to determine the association of COVID-19 infection, its severity and outcome in COVID-19 vaccinated people.
Methods
This was a hospital based prospective cohort study done between March to June 2021 at PBM Associated Group of Hospitals (AGH), Bikaner, Raj. Total 1028 COVID suspected cases consulted in COVID OPD or hospitalized under department of medicine, out of which 146 satisfied the inclusion and exclusion criteria, out of these 146, first 100 cases who gave consent for part of study were selected.
Results
Among 100 COVID-19 infected cases, 49 received first dose while rest got both doses. After first dose of vaccination 42.86% had mild and 32.65% had severe clinical infection while after both doses 80.39% had mild and 11.76% had severe clinical infection. On evaluation of HRCT Chest, after first dose 8.16% had normal 40.82% were in severe category while those who got both doses it was 52.82% 3.92% respectively. Among 49 who got first dose, 10.20% recovered on just home based treatment without any need of hospitalization, while 89.8% got admitted in dedicated COVID hospital out of which 73.47% got recovered and 16.33% died. Among 51 who got both the doses, 66.67% recovered on just home based treatment, while 33.33% required hospitalization out of which 25.49% got recovered and 7.84% died.
Conclusion
After 2nd dose of vaccine there is a significant risk reduction in need of hospitalization and getting severe infection and mortality when compared with first dose only.
europepmc.org
以上显示的是最相近的搜索结果。 查看全部搜索结果